Literature DB >> 8022146

[Flare response on bone scintigraphy in metastatic prostate cancer].

T Aizawa1, M Tochimoto, T Ito, S Tsujino, A Akiyama, K Namiki, M Miki, M Ueda.   

Abstract

Seventy-seven cases of prostate cancer were treated for 5 years at our department and all cases were followed by bone scintigraphy and tumor markers. Of these cases on case of flare response on bone scintigraphy was recognized. A 51-year-old man was hospitalized with chief complaint of lumbago. Serum PAP and gamma-Sm levels were 320 ng/ml and 15 ng/ml, respectively. Prostate biopsy revealed moderately differentiated adenocarcinoma. Bone scintigraphy and CT scan demonstrated multiple bone metastases and lymph nodes involvements. Treatment was started with diethylstilbestrol diphosphate (DES). At one month after the initiation of treatment tumor markers fell down to the normal level and lumbago was diminished, but only serum alkaline phosphatase was elevated and bone scintigraphy showed apparent progression of individual lesions (flare response). The treatment was not altered. At the times after 2, 8, 12 and 36 months successful treatment the bone imaging improved with reduced tracer uptake and no new lesions. The flare response is a healing reaction and is followed apparent improvement. In general, serial bone scintigrams accurately depict the activity of bone metastases in the patients of prostate cancer, but between 1 and 3 months after starting treatment the paradoxical "flare phenomenon" should be taken care.

Entities:  

Mesh:

Year:  1994        PMID: 8022146     DOI: 10.5980/jpnjurol1989.85.815

Source DB:  PubMed          Journal:  Nihon Hinyokika Gakkai Zasshi        ISSN: 0021-5287


  1 in total

1.  Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: Report of a case and case review.

Authors:  Yuko Yasuda; Kodai Kawamura; Kazuya Ichikado; Masakazu Yoshioka
Journal:  Respir Med Case Rep       Date:  2014-10-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.